Helicobacter pylori infection and current clinical areas of contention

Current Opinion in Gastroenterology

Volumn 26, Issue 6, 2010, Pages 618-623

  Malfertheiner, Peter ^a   Selgrad, Michael ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

gastric cancer screening and prevention; Helicobacter pylori; treatment

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; CXCL1 CHEMOKINE; GHRELIN; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; OMEPRAZOLE; PROTON PUMP INHIBITOR; RIFABUTIN; TETRACYCLINE;

ALLERGIC DISEASE; CANCER PREVENTION; CANCER SCREENING; CHINA; DISEASE ASSOCIATION; DRUG EFFICACY; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGH RISK POPULATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IRON DEFICIENCY ANEMIA; JAPAN; KOREA; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; REVIEW; STOMACH CANCER;

ANEMIA, IRON-DEFICIENCY; ANTI-BACTERIAL AGENTS; ASTHMA; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYPERSENSITIVITY; MASS SCREENING; OBESITY; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SEROLOGIC TESTS; STOMACH NEOPLASMS;

EID: 77958474941     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32833efede     Document Type: Review

References (56)

1. Backert S, Selbach M. Role of type IV secretion in Helicobacter pylori pathogenesis. Cell Microbiol 2008; 10:1573-1581.
2. Malfertheiner P, Bornschein J, Selgrad M. Role of Helicobacter pylori infection in gastric cancer pathogenesis: a chance for prevention. J Dig Dis 2010; 11:2-11.
3. Pellicano R, Franceschi F, Saracco G, et al. Helicobacters and extragastric diseases. Helicobacter 2009; 14 (Suppl 1):58-68.
4. Gasbarrini A, Franceschi F, Tartaglione R, et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 1998; 352:878.
5. Kodama M, Kitadai Y, Ito M, et al. Immune response to CagA protein is associated with improved platelet count after Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura. Helicobacter 2007; 12:36-42.
6. Ferrara M, Capozzi L, Russo R. Effect of Helicobacter pylori eradication on platelet count in children with chronic idiopathic thrombocytopenic purpura. Hematology 2009; 14:282-285.
7. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56:772-781.
8. Huang X, Qu X, Yan W, et al. Iron deficiency anaemia can be improved after eradication of Helicobacter pylori. Postgrad Med J 2010; 86:272-278.
9. Yuan W, Li Y, Yang K, et al. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol 2010; 45:665-676
10. In this meta-analysis of 16 randomized controlled trials with 956 patients included, the authors conclude that treatment of H. pylori infection could be effective in improving anemia and iron status in IDA patients infected by H. pylori, particularly in patients with moderate or severe anemia.
11. Qu XH, Huang XL, Xiong P, et al. Does Helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis. World J Gastroenterol 2010; 16:886-896.
12. Choi JW, Son BK. Soluble transferrin receptor concentration isnotsuperiorto log ferritin for evaluating erythropoiesis in adolescents with iron deficiency anemia. Clin Chim Acta 2005; 355:83-89.
13. Choi JW. Sensitivity, specificity, and predictive value of serum soluble transferrin receptor at different stages of iron deficiency. Ann Clin Lab Sci 2005; 35:435-439.
14. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989; 299:1259-1260.
15. Reibman J, Marmor M, Filner J, et al. Asthma is inversely associated with Helicobacter pylori status in an urban population. PLoS One 2008; 3:e4060.
16. Chen Y, Blaser MJ. Inverse associations of Helicobacter pylori with asthma and allergy. Arch Intern Med 2007; 167:821-827.
17. Blaser MJ, Chen Y, Reibman J. Does Helicobacter pylori protect against asthma and allergy? Gut 2008; 57:561-567.
18. Codolo G, Mazzi P, Amedei A, et al. The neutrophil-activating protein of Helicobacter pylori down-modulates Th2 inflammation in ovalbumin-induced allergic asthma. Cell Microbiol 2008; 10:2355-2363.
19. D'Elios MM, Codolo G, Amedei A, et al. Helicobacter pylori, asthma and allergy. FEMS Immunol Med Microbiol 2009; 56:1-8.
20. Harris PR, Wright SW, Serrano C, et al. Helicobacter pylori gastritis in children is associated with a regulatory T-cell response. Gastroenterology 2008; 134:491-499.
21. Robinson K, Kenefeck R, Pidgeon EL, et al. Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses. Gut 2008; 57:1375-1385.
22. Del Guidice G, Malfertheiner P, Rappuoli R. Development of vaccines against Helicobacter pylori. Expert Rev Vaccines 2009; 8:1037-1049.
23. Weigt J, Malfertheiner P. Influence of Helicobacter pylori on gastric regulation of food intake. Curr Opin Clin Nutr Metab Care 2009; 12:522-525.
24. Tatsuguchi A, Miyake K, Gudis K, et al. Effect of Helicobacter pylori infection on ghrelin expression in human gastric mucosa. Am J Gastroenterol 2004; 99:2121-2127.
25. Yamaoka Y, Kato M, Asaka M. Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern Med 2008; 47:1077-1083.
26. Graham DY, Asaka M. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. J Gastroenterol 2010; 45: 1-8.
27. Choi IJ. Gastric cancer screening and diagnosis. Korean J Gastroenterol 2009; 54:67-76.
28. di MF, Cavallaro LG. Noninvasive tests in gastric diseases. Dig Liver Dis 2008; 40:523-530.
29. Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004; 109:138-143.
30. Bornschein J, Rokkas T, Selgrad M, Malfertheiner P. Helicobacter pylori and clinical aspects of gastric cancer. Helicobacter 2009; 14 (Suppl 1):41-45.
31. Yeh JM, Kuntz KM, Ezzati M, Goldie SJ. Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer 2009; 124:157-166.
32. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372:392-397.
33. Vaananen H, Vauhkonen M, Helske T, et al. Nonendoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 2003; 15:885-891.
34. Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005; 54:764-768.
35. Miki K, Fujishiro M, KodashimaS, Yahagi N. Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. Dig Endosc 2009; 21:78-81.
36. Ren JS, Kamangar F, Qiao YL, et al. Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort. Gut 2009; 58:636-642.
37. Asaka M, Kato M, Takahashi S, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010; 15:1-20.
38. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24:1587-1600.
39. de Vries AC, Kuipers EJ. Review article: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther 2007; 26 (Suppl 2): 25-35.
40. de Vries AC, Kuipers EJ, Rauws EA. Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn? Am J Gastroenterol 2009; 104:1342-1345.
41. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102:1808-1825.
42. Rokkas T, Sechopoulos P, Robotis I, et al. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009; 104:21-25.
43. Selgrad M, Kandulski A, Malfertheiner P. Helicobacter pylori: diagnosis and treatment. Curr Opin Gastroenterol 2009; 25:549-556.
44. De FV, Zullo A, Ierardi E, et al. Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits. J Antimicrob Chemother 2010; 65:327-332.
45. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59:1143-1153.
46. De Mario F, Margiotta M, Zullo A, et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother 2007; 59:783-785.
47. Zullo A, De Francesco V, Hassan C, et al. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007; 56:1353-1357.
48. Gatta L, Vakil N, Leandro G, et al. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis in adults and children. Am J Gastroenterol 2009; 104:3069-3079.
49. Sirimontaporn N, Thong-Ngam D, Tumwasorn S, Mahachai V. Ten-day sequential therapy of Helicobacter pylori infection in Thailand. Am J Gastroenterol 2010; 105:1071-1075.
50. Essa S, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, nonbismuth-containing 'concomitant therapy' versus triple therapy for Heliocbacter pylori eradication. Helicobacter 2009; 14:109-118.
51. Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98:562-567.
52. Sun Q, Liang X, Zheng Q, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter 2010; 15:233-238.
53. Ford AC, Malfertheiner P, Giguere M, et al. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008; 14:7361-7370.
54. Liou JM, Lin JT, Chang CY, et al. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pyloriinfection: a randomised comparative trial with crossover design. Gut 2010; 59:572-578.
55. Cambau E, Allerheiligen V, Coulon C, et al. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J Clin Microbiol 2009; 47:3600-3607.
56. Zagari RM, Bianchi-Porro G, Fiocca R, et al. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER study. Gut 2007; 56:475-479.